Lodge Hill Capital Decreased Its Cummins (CMI) Holding; Immunocellular Therapeutics LTD. (NYSEAMERICAN:IMUC) Sellers Increased By 6.34% Their Shorts

February 26, 2018 - By Michael Collier

Immunocellular Therapeutics LTD. (NYSEAMERICAN:IMUC) had an increase of 6.34% in short interest. IMUC’s SI was 2.40M shares in February as released by FINRA. Its up 6.34% from 2.26M shares previously. With 1.25 million avg volume, 2 days are for Immunocellular Therapeutics LTD. (NYSEAMERICAN:IMUC)’s short sellers to cover IMUC’s short positions. The stock increased 1.85% or $0.0049 during the last trading session, reaching $0.2699. About 665,991 shares traded. ImmunoCellular Therapeutics, Ltd. (NYSEAMERICAN:IMUC) has declined 86.26% since February 26, 2017 and is downtrending. It has underperformed by 102.96% the S&P500.

Lodge Hill Capital Llc decreased Cummins Inc (CMI) stake by 11.01% reported in 2017Q3 SEC filing. Lodge Hill Capital Llc sold 19,820 shares as Cummins Inc (CMI)’s stock rose 1.30%. The Lodge Hill Capital Llc holds 160,180 shares with $26.92 million value, down from 180,000 last quarter. Cummins Inc now has $28.36 billion valuation. The stock increased 1.28% or $2.17 during the last trading session, reaching $171.7. About 807,449 shares traded. Cummins Inc. (NYSE:CMI) has risen 43.32% since February 26, 2017 and is uptrending. It has outperformed by 26.62% the S&P500.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune therapies for the treatment of various cancers. The company has market cap of $9.50 million. The Company’s lead product candidate is ICT-107, a dendritic cell immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). It currently has negative earnings. The firm is also developing ICT-140, a DC immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers.

Analysts await Cummins Inc. (NYSE:CMI) to report earnings on May, 1. They expect $2.86 earnings per share, up 21.19% or $0.50 from last year’s $2.36 per share. CMI’s profit will be $472.41 million for 15.01 P/E if the $2.86 EPS becomes a reality. After $3.03 actual earnings per share reported by Cummins Inc. for the previous quarter, Wall Street now forecasts -5.61% negative EPS growth.

Lodge Hill Capital Llc increased Lamb Weston Hldgs Inc stake by 225,140 shares to 546,140 valued at $25.61M in 2017Q3. It also upped Reliance Steel & Aluminum Co (Call) (NYSE:RS) stake by 185,167 shares and now owns 450,000 shares. Oracle Corp (Call) (NYSE:ORCL) was raised too.